Allogeneic Viral Specific T Cells Are Safe and Can be Efficient in the Treatment of Infections in Solid Organ Transplant Recipients

Recipients of solid organ transplant (SOT) are at risk of viral infection and development of viral-driven malignancy (EBV-PTLD) due to immunosuppressive medications to prevent organ rejection. Treatments are limited by poor efficacy and organ toxicity, and reduction in immunosuppression to enable the patient's immune system fight the infection risks organ rejection. Allogeneic viral specific T-cells (VST) have been used to treat viral infections after stem cell transplant, and here we evaluated VST for the treatment of CMV, ADV, EBV-PTLD and BK in six SOT (heart, liver, kidney, lung) recipients.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Adam S. Nelson, Teri Clark, Diana Clark, Olivia Grimley, Jeremy D. Rubinstein, Xiang Zhu, Jamie Wilhelm, Catherine M. Bollard, Patrick J. Hanley, Michael D. Keller, Jose A. Cancelas, Stella M. Davies, Carolyn Lutzko, Michael S. Grimley Tags: 528 Source Type: research